Humacyte, Inc.
NASDAQ:HUMABiotechnology
-$0.03 today
- Market cap
- $138.90M
- Beta
- 2.46
- P/E (TTM)
- -1.9
- EPS (TTM)
- -$0.49
Volume 3.91M
Average 8.14M
HUMA Depreciation & Amortization
Non-cash asset write-downs added back to net income because no cash left the business.
Humacyte, Inc.NASDAQ: HUMA
Depreciation & Amortization · Q1 FY2026 · quarter ended Mar 2026
Depreciation & amortization dips below year-ago levels
Q1 FY2026 depreciation & amortization of $1.79M fell 2.3% year over year, behind the +34.4% change in trailing-twelve-month depreciation & amortization. Sequentially, it rose 33.5% from the prior quarter. Over 3 fiscal years it compounded at -13.4% a year.
Context
- Depreciation & amortization amounted to 261.4% of revenue in FY2025.
- Depreciation & amortization increased in 0 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from -2.3% toward the trailing-twelve-month pace of +34.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Depreciation & Amortization history
USD · from the cash flow
- Latest · FY2025
- 5.33M USD
- Year-over-year change
- -25.9%
- 4-year CAGR
- -10.3%
| Period | Period end | Depreciation & Amortization | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 5.33M | -25.9% |
| FY2024 | 2024-12-31 | 7.19M | -6.9% |
| FY2023 | 2023-12-31 | 7.72M | -6.0% |
| FY2022 | 2022-12-31 | 8.21M | -0.4% |
| FY2021 | 2021-12-31 | 8.24M | — |
Depreciation & Amortization vs competitors
How HUMA compares with its peers on the latest reported figures
- HUMA's LTM Mar 2026 depreciation & amortization of $6.86M is the 2nd largest of the 11 companies compared; the peer median is $1.69M.
- Its year-over-year change of +34.4% is the highest of 10, against a peer median of -4.7%.
- Depreciation & amortization amounts to 340.1% of revenue for HUMA, versus a peer median of 6.4%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $8.66M | +9.7% | — | 4.0% | |
| LTM Mar 2026 | $6.86M | +34.4% | -13.4% | 340.1% | |
| LTM Mar 2026 | $6.32M | -1.1% | +23.7% | — | |
| LTM Mar 2026 | $3.61M | -20.6% | -13.1% | 9.9% | |
| LTM Mar 2026 | $2.88M | -16.2% | +25.6% | 6.4% | |
| LTM Mar 2026 | $2.84M | -8.0% | -25.0% | 10.1% | |
| LTM Mar 2026 | $531.13K | +15.1% | -4.3% | — | |
| LTM Mar 2026 | $416K | +0.0% | +17.0% | — | |
| LTM Mar 2026 | $284K | -92.5% | +29.3% | 4.9% | |
| LTM Mar 2026 | $223K | -4.7% | -1.1% | — | |
SGMTSagimet Biosciences Inc. | LTM Mar 2026 | $0 | — | — | — |
| Peer median (excluding HUMA) | $1.69M | -4.7% | +7.9% | 6.4% | |
Competitors are the stored peer set for HUMA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (26.48M) | (11.97M) | (110.78M) | (148.7M) | (40.83M) |
| Depreciation & Amortization | 8.24M | 8.21M | 7.72M | 7.19M | 5.33M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 10.15M | 6.18M | 6.83M | 6.14M | 9.75M |
| Change in Working Capital | (557K) | 1.03M | 6.57M | 311K | (23.4M) |
| Accounts Receivables | (63K) | 145K | 31K | 0 | (261K) |
| Inventory | 0 | 0 | 0 | 0 | (21.83M) |
| Accounts Payables | (197K) | (509K) | 4.81M | (1.96M) | 973K |
| Other Working Capital | (297K) | 1.39M | 1.73M | 2.27M | (2.28M) |
| Other Non-Cash Items | (72.54M) | (74.59M) | 16.35M | 36.94M | (55.9M) |
| Operating Cash Flow | (81.19M) | (71.13M) | (73.31M) | (98.12M) | (105.04M) |
| Capital Expenditures | (220K) | (1.05M) | (2.28M) | (1.57M) | (884K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | (8M) | (10.11M) | 0 | 0 | 0 |
| Sales of Investments | 0 | 16M | 2.11M | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (8.22M) | 4.85M | (173K) | (1.57M) | (884K) |
| Debt Repayment | 27.93M | (1.98M) | 5.7M | (2.58M) | 36.39M |
| Common Stock Issued | 598K | 535K | 566K | 45.93M | 113.44M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 239.05M | 535K | (1.76M) | 27.71M | (88.34M) |
| Financing Cash Flow | 266.98M | (1.45M) | 4.51M | 114.18M | 61.49M |
| Effect of Forex Changes | 0 | 0 | (209K) | 0 | 0 |
| Net Change in Cash | 177.57M | (67.73M) | (69.18M) | 14.49M | (44.44M) |
| Free Cash Flow | (81.41M) | (72.18M) | (75.59M) | (99.69M) | (105.93M) |
Humacyte, Inc.
NASDAQ:HUMA
Intrinsic Alpha fair value
Locked
Current Price
$0.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.